AveXis is a clinical-stage gene therapy company developing innovative treatments for rare and life-threatening genetic diseases.    Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.
AveXis is a rapidly growing leader among gene therapy biotech companies and continues to establish relationships with academics, biotechnology and pharmaceutical companies, and healthcare investors.

Type
Subsidiary
Parent Company
Novartis
HQ
Bannockburn, US
Founded
2010
Website
avexis.com
AveXis was founded in 2010 and is headquartered in Bannockburn, US
Report incorrect company information

Key People/Management at AveXis

Sean Nolan

Sean Nolan

CEO
Phillip Donenberg

Phillip Donenberg

CFO
Sukumar Nagendran

Sukumar Nagendran

CMO
Brian Kaspar

Brian Kaspar

CSO
Rick Modi

Rick Modi

CBO
R.a. Session

R.a. Session

Svp
Show more

AveXis Office Locations

AveXis has an office in Bannockburn
Bannockburn, US (HQ)
200 2275 Half Day Rd
Bannockburn, US (HQ)
160 2275 Half Day Rd
Show all (2)
Report incorrect company information

AveXis Financials and Metrics

Summary Metrics

In total, AveXis had raised $75 m. AveXis is a subsidiary of Novartis

AveXis Financials

Annual
USDFY, 2016

General and administrative expense

24.5 m

R&D expense

58.9 m

Operating expense total

83.4 m

EBIT

(83.4 m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

General and administrative expense

4.8 m5.4 m7.1 m9.6 m

R&D expense

16.1 m10.4 m14.1 m20.3 m

Operating expense total

20.9 m15.8 m21.2 m30 m
Annual
USDFY, 2016

Cash

240.4 m

Current Assets

245.2 m

PP&E

24.2 m

Total Assets

270.6 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

148.2 m131.4 m263.6 m204.5 m

Current Assets

149.7 m134.4 m267.5 m211.7 m

PP&E

5.9 m8.3 m16.8 m33.7 m

Total Assets

156 m143.1 m284.8 m247.2 m
Annual
USDFY, 2016

Net Income

(83 m)

Depreciation and Amortization

64.6 k

Accounts Payable

958 k

Cash From Operating Activities

(48 m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(20.8 m)(15.7 m)(21.1 m)(29.7 m)

Depreciation and Amortization

11 k

Accounts Payable

580.7 k1.1 m3.7 m11.8 m

Cash From Operating Activities

(7.7 m)
Show all financial metrics
Report incorrect company information

AveXis News and Updates

UPDATE 3-Novartis bets big on gene therapy with $8.7 bln AveXis deal

* Acquisition fuels busy year for biotechnology deal-making (Adds comments from analysts, details of advisers, shares)

UPDATE 2-Novartis bets big on gene therapy with $8.7 bln AveXis deal

* Acquisition fuels busy year for biotechnology deal-making (Adds more on gene therapy, biotech M&A context, CEO comments)

BRIEF-Novartis Enters Agreement To Acquire AveXis For $8.7 Bln

* NOVARTIS ENTERS AGREEMENT TO ACQUIRE AVEXIS INC. FOR USD 8.7 BN TO TRANSFORM CARE IN SMA AND EXPAND POSITION AS A GENE THERAPY AND NEUROSCIENCE LEADER
Report incorrect company information